FEEDBACK
PLEASE WAIT ...
CLOSE
CLOSE

Country

Industries

  • Medicine ‎1
    • Pharmaceuticals ‎1

Contact Info

Location

Viroclinics Xplore

  • 1Product
  • 1Types
  • 1Industry

About Company

Viroclinics Biosciences is a leading diagnostic and clinical trial operation service company supporting clinical and preclinical studies for drug and vaccine development for prevention and treatment of virus infections. Our mission is to improve human and animal health by serving the biopharmaceutical industry with state-of-the-art diagnostics, operational and logistical services, custom-made models in preclinical and clinical drug testing, and expert

Viroclinics Biosciences is a leading diagnostic and clinical trial operation service company supporting clinical and preclinical studies for drug and vaccine development for prevention and treatment of virus infections. Our mission is to improve human and animal health by serving the biopharmaceutical industry with state-of-the-art diagnostics, operational and logistical services, custom-made models in preclinical and clinical drug testing, and expert advice on development of antivirals and vaccines. We offer a full range of virology services for new drug development programs and post-marketing surveillance of existing drugs and vaccines, ranging from traditional virology assays to the latest deep sequencing protocols for a very broad range of viruses. Our BSL2 and BSL3 labs enable us to perform analysis according to international ISO 15189 accreditation, GLP and GCLP. Viroclinics Biosciences was founded in 2001. It has since grown into a company exceeding 140 FTE of dedicated scientists and technical experts, and operates within a network of key opinion leaders and consultants. In 2010 the ISO 15189 quality system was accredited. With the implementation of this quality system Viroclinics was able to generate high quality assay data in clinical studies that were used in registration filings for new vaccines and antiviral drugs by large and small pharmaceutical companies. As of September 2012 the company migrated to the Rotterdam Science Tower, a new high tech science facility. At this new location the company occupies 4500 m2 office space and new laboratory facilities, accommodating BSL 2 and BSL 3 work. In 2017 the company expanded its footprint with a 1500 m2 lab in Schaijk, dedicated to preclinical services at BSL 2 and BSL 3 level. In Schaijk the company also implemented a GAP III facility dedicated for work with polio viruses.

Products

Coronavirus Vaccine Candidate

MEDICINE - PHARMACEUTICALS   |  COVID-19 VACCINE

Coronavirus Vaccine Candidate

Properties :

Immune system enhancement

Application :

Coronavirus,COVID-19

Analytical Reports